



FOR IMMEDIATE RELEASE

Molecular Targeting Technologies, Inc. features EBTATE advances at the 2022 SNMMI meeting in Vancouver, BC.

West Chester, PA, June 9, 2022 -- Molecular Targeting Technologies, Inc. (MTTI), a clinical stage oncology company, will highlight advances on its EvaThera™ radiotheranostics platform at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) meeting in Vancouver, BC, on June 11-15, 2022 (Exhibit booth #1715). The EvaThera platform includes EBTATE™ (¹⁷⁷Lu-DOTA-EB-TATE) for Neuroendocrine Neoplasms (NENs), Hürthle cell thyroid and nasopharyngeal cancers and EBRGD™ (¹⁷⁷Lu-DOTA-EB-RGD) for glioblastoma multiforme and non-small cell lung cancer

A video featuring the EBTATE story (see link below) will be released at the meeting.

<https://www.youtube.com/watch?v=4JTRUgqVZGk>

In addition, two abstracts highlighting MTTI's EBTATE & our PET imaging agent, ¹⁸F-glucarate, were selected for oral and poster presentations:

- (i) **Evaluation of Safety, Biodistribution and Dosimetry of a long-Acting Radiolabeled Somatostatin Analogue ¹⁷⁷Lu-DOTA-EB-TATE with and without Amino Acid Infusion** by Qingxing Liu, Yuanyuan Jiang, Koon Pak, Guochang Wang, Jingjing Zhang, Xiaoyuan Chen and Zhaohui Zhu (oral presentation)

EBTATE treatment without amino acid infusion, normally used in current treatments to block drug impact on non-target organs, has acceptable, minor effects on the kidneys and does no harm to kidney function. EBTATE may significantly improve patient comfort vs. current treatments.

- (ii) **Assessment of ¹⁸F-glucarate as a potential PET tracer for cancer imaging** by Junling Li, Huaiyu Zheng, Levi Beverly, Brian Gray, Koon Pak and Chin K. Ng (poster presentation)

¹⁸F-glucarate uptake in both *in vitro* and *in vivo* correlated well with the degree of cell death and shows early tumor response to chemotherapy, enabling faster assessment of treatment efficacy.

About MTTI

MTTI is a privately held, rapidly growing, well financed, clinical stage biotech developing targeted radiotherapeutics and diagnostics for rare cancers. We are committed to building value by acquiring and translating innovative imaging, radiopharmaceutical and theranostic assets to improve human health, reduce healthcare costs and reward stakeholders. MTTI expects to be orchestrating multiple clinical trials in 2022. For more information: www.mtarget.com; www.evathera.com

Contact: Chris Pak, Email: cpak@mtarget.com